Number：   YB1-ADC-Her2、YB1-ADC-PDL1、YB1-ADC-CD47

Medicine：   Conjugation of HER2 antibody to YB1 surface

Indication：   HER2 positive breast cancer, PDL1 positive melanoma, CD47 high expression tumor

Shortcoming：
                It can not overcome the limitations of antibody drugs：
                1. The relative concentration of tumor target is low;
                2. Drug metabolism is fast and half-life is short;

Introduction：   In addition to carrying various warhead drugs, YB1 can also use the antibody drug conjugate (ADC) mode: yb1-adc products regulate the expression of YB1 internal genes, and present the antibody sequence to the appearance of YB1 for display, so as to realize the antibody coupling effect. At present, it has entered the preclinical research and development stage.

Academic：   ADC is a kind of drug that connects the bioactive cytotoxic drugs to mAb by chemical bond. MAb as carrier targets the drug to transport to target cells.
       Currently, FDA approved four ADC drugs to be listed: in 2011, adetris (brentuximab vedotin) jointly developed by Takeda /seatte genetics was used to treat Hodgkin's lymphoma and systemic anaplastic large cell lymphoma; in 2013, kadcyla of Roche (ADO trastuzumab emtansine, used for HER2 positive breast cancer); in 2017, wasponsa (inotuzumab ozogamini), For single drug treatment of relapsed or refractory CD22 + adult B-cell precursor acute lymphoblastic leukemia (all)); in 2018, luxexiti (moxetumab pasudotox tdfk) of AstraZeneca was used for the treatment of adult patients who had received at least two systemic, recurrent or refractory hair cell leukemia (HCl).

Number：   YB1-rt-PA（Modified version YB1 for thrombolysis）

Medicine：   Recombinant urokinase（rt-PA）

Indication：   Various thrombi

Shortcoming：   RT-PA, a thrombolytic drug, has a short half-life of only 4-8 minutes, which can not alleviate the incidence of acute thrombosis.

Introduction：   YB1 can be used not only in the field of tumor treatment, but also in the treatment of various thrombosis. YB1 RT PA is the first generation of targeted thrombolysis products. It is mainly characterized by carrying through YB1 and releasing urokinase at the thrombus site to achieve the effect of rapid targeted release of thrombolytic drugs. Urokinase is produced by the kidney in the human body and can directly activate plasminogen into plasmin. In medicine, urokinase is the first generation of natural thrombolytic drug extracted from urine.

Academic：   According to China cardiovascular disease report 2019, cardiovascular disease is the leading cause of death in Chinese population. Worldwide, the number of deaths due to cardiovascular and cerebrovascular diseases such as cerebral thrombosis is about 12 million every year, which is close to a quarter of the total death toll. It is the number one killer of human health. The number of cardiovascular diseases is 330 million, including 13 million stroke, 11 million coronary heart disease, 5 million pulmonary heart disease, 8.9 million heart failure, 2.5 million rheumatic heart disease, 2 million congenital heart disease, 45.3 million lower extremity artery disease and 245 million hypertension. Thrombotic diseases, as one of the main forms of cardiovascular and cerebrovascular diseases, show high incidence rate, high recurrence rate, high disability rate and high mortality rate. Clinically, antiplatelet aggregation, anticoagulation and thrombolysis are the main methods for the treatment of stroke.
Data show that the scale of China's antithrombotic drug market maintains a steady and rapid growth trend. From 2014 to 2018, the market scale increased from 12.7 billion yuan to 20 billion yuan, with a compound growth rate of more than 12%.

The mechanism of urokinase rt-PA to dissolve thrombus

Green fluorescent signal: YB1 can quickly accumulate in the thrombus position and release thrombolytic enzyme

Schematic diagram of YB1 releasing rt-PA to dissolve thrombus